Enjoy complimentary customisation on priority with our Enterprise License!
The human microbiome therapeutics market size is projected to reach a value of USD 1001.56 billion in 2027 with accelerating at a CAGR of 30.11% between 2022 and 2027.
Analysis Period | 2017-2027 |
Market Size (2017) Historic Year | USD 79.53 billion |
Market Size (2027) - Forecasted Year | USD 1001.56 billion |
Historic Opportunity (2017-2021) | USD 131.27 billion |
Historic CAGR | 27.60 % |
Forecasted Opportunity (2023-2027) | USD 732.95 billion |
Market Opportunity Transformation Growth | 1.00 % |
Market Opportunity Capitalization | USD 864.22 billion |
The report offers extensive research analysis on the Human Microbiome Therapeutics Market, with a categorization based on Product , including Probiotics, Prebiotics, Medical foods, and Prescription drugs. It further segments the market by Application, encompassing Gastrointestinal disorders, Infectious diseases, and Others. Additionally, the report provides geographical segmentation, covering North America, Europe, Asia, and Rest of World (ROW).
To learn more about this report, Download Report Sample
The burgeoning incidence of chronic diseases acts as the primary driving force propelling the expansion of the human microbiome therapeutics market. The continuous advancements in microbiome therapeutics are a direct response to the escalating global prevalence of chronic conditions such as diabetes, hypertension, and obesity. These conditions not only present immediate health risks but also serve as precursors for the onset of other severe diseases. The evolving landscape of advancements in microbiome therapeutics is increasingly recognized as a crucial avenue to address and mitigate the complications arising from these chronic ailments.
Hypertension, often asymptomatic, can be attributed to a blend of poor lifestyle choices and genetic predispositions. Growing evidence underscores an association between modifications in the human microbiome and hypertension. Consequently, there exists a pressing need to develop microbiome-based therapies to address the symptoms and treatment of hypertension.
Research demonstrates that middle-aged, obese men face a 50%-60% higher risk of heart failure compared to their non-obese counterparts. A significant portion of obesity can be traced back to the composition of the gut microbiome. Consequently, in the upcoming years, we anticipate a surge in endeavors aimed at harnessing and cultivating the human microbiome. This emphasis stems from the understanding that disruptions in the normal gut microbiota, often triggered by the rising prevalence of chronic diseases, will drive the growth of the global human microbiome therapeutics market during the forecast period. The focus on gut microbiome treatments and innovative microbiome-based therapeutics will likely intensify in response to these emerging market trends and analysis for health challenges.
Human Microbiome Therapeutics Market Future Outlook
As this sector progresses, increased collaboration among startup company and established entities is expected, fueling innovation in personalized medicine and novel microbiome-related medication. The application of qualitative research methodologies will aid in exploring the effects of microorganisms and the efficacy of dietary supplements in addressing various diseases. Moreover, the integration of top-down and bottom-up design strategies will further optimize methodology in microbiome therapeutics, ensuring effective solutions at the point of sale for improved healthcare outcomes. The exploration of treatments such as fecal microbiota transplant is poised to contribute significantly to disease management, emphasizing the role of biotechnology in healthcare advancements.
The probiotics segment was the largest segment and was valued at USD 25.89 million in 2017. Probiotics are live microorganisms that confer health benefits on the host when administered in adequate amounts. Probiotics are bacteria and yeast that help maintain a healthy microbial balance in the intestines of humans. Probiotics are generally found in yoghurt and other fermented foods. Probiotic biome supplements are a way to add good bacteria to the body, as they contain certain health benefits, such as destroying disease-causing cells, producing vitamins, and helping digestion. The Biome probiotic also enhance the immune system and protect proteins and lipids from oxidation damage.
Furthermore, a significant catalyst for growth stems from the expanding geriatric population, more prone to chronic gastrointestinal disorders, where gut microbiome treatments play a pivotal role in alleviating such issues.The application of microbiome therapeutics for gastrointestinal disorders involving gut bacteria probiotics is poised to play a crucial role in addressing these specific health challenges.The increased focus on harnessing probiotic biome for managing gastrointestinal disorders highlights a growing trend in the market analysis of human microbiome therapeutics. This emphasis reflects the ongoing market growth analysis, showcasing the rising recognition of gut microbiome treatments and their substantial influence on overall health. It signifies a promising avenue within the domain of human microbiome therapeutics, indicating a notable market growth and trends towards understanding and leveraging the potential impact of gut microbiome treatments on healthcare and well-being.
North America is estimated to contribute 41% to the growth of the global market during the forecast period. The human microbiome therapeutics market in North America is expected to experience a double-digit growth rate, but it is expected to be slower than in Europe and Asia.
Microbiome drug development involves creating therapeutic interventions that target the human microbiome, the complex community of microorganisms residing within the body. These microorganisms play crucial roles in maintaining health, influencing various bodily functions, and impacting the immune system, metabolism, and even brain function. Factors such as significant investments in microbiome drug development (R & D) of novel therapeutic techniques and high incidences of gastrointestinal and metabolic disorders and immunological disorders drive the market in the region.
Owing to the increasing prevalence of gastrointestinal, metabolic, and immunological disorders, vendors are undertaking different business strategies, including collaborations, for the evaluation of the potency of their drug molecules for the treatment of different types of cancers. Therefore, an increased number focus on clinical research is expected to accelerate the growth of the human microbiome therapeutics market in the region during the forecast period.
To understand geographic trends Download Report Sample
The Human Microbiome Therapeutics Market is fragmented in nature. Some significant players include 4D pharma Plc, BiomX Inc., Eligo Bioscience, ENTEROME SA, Evelo Biosciences Inc.
The market research and growth report also includes detailed analyses of the competitive landscape of the market and information about 15 market companies, including:
Evogene Ltd., Ferring BV, Finch Therapeutics Group Inc., Flightpath Biosciences, Johnson and Johnson Services Inc., MaaT Pharma, Microbiotica Ltd., OptiBiotix Health Plc, PureTech Health Plc, Second Genome Therapeutics, Seres Therapeutics Inc., Synlogic Inc., Takeda Pharmaceutical Co. Ltd., YSOPIA Bioscience, and Locus Biosciences Inc.
The human microbiome therapeutics market forecast market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2017 - 2027.
Human Microbiome Therapeutics Market Scope |
|
Report Coverage |
Details |
Page number |
159 |
Base year |
2022 |
Historic period |
2017 - 2021 |
Forecast period |
2023-2027 |
Growth momentum & CAGR |
Accelerate at a CAGR of 30.11% |
Market growth 2023-2027 |
USD 732.95 million |
Market structure |
Fragmented |
YoY growth 2022-2023(%) |
28.29 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 41% |
Key countries |
US, Germany, France, UK, and Japan |
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
Key companies profiled |
4D pharma Plc, BiomX Inc., Eligo Bioscience, ENTEROME SA, Evelo Biosciences Inc., Evogene Ltd., Ferring BV, Finch Therapeutics Group Inc., Flightpath Biosciences, Johnson and Johnson Services Inc., MaaT Pharma, Microbiotica Ltd., OptiBiotix Health Plc, PureTech Health Plc, Second Genome Therapeutics, Seres Therapeutics Inc., Synlogic Inc., Takeda Pharmaceutical Co. Ltd., YSOPIA Bioscience, and Locus Biosciences Inc. |
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this market research report to meet your requirements.
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.